Global X Genomics & Biotechnology ETF
GNOM

$11.32

2.08%

Market Cap: $84.4M

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

7% more funds holding

Funds holding: 59 [Q1] → 63 (+4) [Q2]

1.64% more ownership

Funds ownership: 29.53% [Q1] → 31.17% (+1.64%) [Q2]

5% less capital invested

Capital invested by funds: $31.1M [Q1] → $29.6M (-$1.47M) [Q2]

26% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 19

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for GNOM.

See Analyst Rankings

Financial journalist opinion

The 3 Best Gene Editing Stocks to Buy in July 2024

Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier genes in an attempt to cure diseases or help the body fight disease.

The 3 Best Gene Editing Stocks to Buy in July 2024

Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life

Genomics is the future of medicine. With it, companies are racing to shed light on human health and disease.

Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life

3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire

Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023.

3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire

GNOM: Genomics Still Waiting For Its 'ChatGPT' Moment

GNMO invests across companies benefiting from advancements in the field of genomics within biotechnology. The fund's historical performance has been poor amid volatile stock prices for underlying holdings. Genomics may be the future, but still missing a blockbuster application to drive a wave of bullish momentum into the segment.

GNOM: Genomics Still Waiting For Its 'ChatGPT' Moment

3 Stocks That Could Be the Next Big Thing in Gene Editing

Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks.

3 Stocks That Could Be the Next Big Thing in Gene Editing

3 Gene Editing Stocks With Unprecedented Surge Potential

Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions.

3 Gene Editing Stocks With Unprecedented Surge Potential

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential

Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential

VettaFi Voices On: The Outlook for 2024

Good morning, VettaFi Voices! We are a week out from the VettaFi 2024 Market Outlook Symposium on December 14, which will feature a range of ETF industry leaders discussing their expectations for different areas of the financial markets and the economy in 2024.

VettaFi Voices On: The Outlook for 2024

See News Rankings